Hangzhou Reprogenix Bioscience, Inc
1 clinical trials · Sponsor
◉ Watch Hangzhou Reprogenix Bioscience, Inc
| Record | Firm | Date |
|---|---|---|
| Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus (NCT06731218) | Hangzhou Reprogenix Bioscience, Inc | 2025-02-17 |
Track Hangzhou Reprogenix Bioscience, Inc automatically
Every clearance here is in the API, with alerts when new ones post.